Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025Current Gene Therapy

Transcriptomic Signatures in TP53 Positive and Negative Tumor Samples in NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMiao XieBLBaoguang LiuZCZiyi Chen

Discussion

Loading...

Member takes

Overview

Analysis reveals a TP53-related gene signature that predicts overall survival and immune response in NSCLC patients, suggesting implications for immunotherapy decisions.

Key Points

  • The 12-gene signature predicts survival outcomes and immune response patterns in NSCLC patients, enhancing precision oncology approaches.
  • A total of 535 differentially expressed genes were identified in TP53 mutated samples, with 12 genes validated for prognostic features using LASSO analysis.
  • Gene expression profiles were sourced from the GEO and TCGA databases, involving 1,095 non-small cell lung cancer samples.
  • The findings highlight the correlation between TP53 mutation status and immune microenvironment changes, providing insights for immunotherapy strategies.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68c23595b210217d647718fahttps://doi.org/10.2174/0115665232357300250805021330
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development and validation of a hypoxia-immune-based microenvironment gene signature for predicting survival in non-small cell lung cancer2025 · 2 citations
  2. 2PROGNOSTIC SIGNIFICANCE OF TP53 AND PD-L1 DEPENDING ON THE TYPE OF ADJUVANT THERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER2025
  3. 3Dissecting the immune evasion and therapeutic resistance mechanisms in EGFR/TP53 co-mutated non-small cell lung cancer: implications for targeted and immunotherapy strategies2025 · 5 citations
  4. 4A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia2025
  5. 5Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer2025 · 6 citations